All In Biotech

Drug Trial Radar · NCT01004263

A Study to Evaluate the Safety and Tolerability of Rizatriptan for Long Term Treatment of Acute Migraine in Children and Adolescents (MK-0462-086 AM3)

A Worldwide, Open Label, Clinical Trial to Examine the Long Term Safety and Tolerability of Rizatriptan in Pediatric Migraineurs for the Treatment of Migraine With or Without Aura

Last checked: Nov 19, 2026Latest source record: Apr 22, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

674

Actual

Start

Dec 1, 2009

Primary completion

Apr 18, 2011

Study completion Apr 18, 2011

Sponsor

Lead sponsor
Organon and CoIndustry
Sponsor type
Industry
First posted
Oct 29, 2009

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 12 years, up to 17 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To provide long term safety data for rizatriptan in children and adolescents. The primary hypothesis of the study is that rizatriptan is well tolerated in the long term treatment of acute migraine in pediatric patients age 12-17 years.

Conditions

  • Acute Migraine With or Without Aura in Adolescents

Interventions

  • rizatriptan benzoateDrug

    Single dose of 5 mg or 10 mg orally disintegrating tablet at onset of migraine attack

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Adverse Events (AEs) Within 24 Hours Post Any DoseTime frame: Up to 24 hours post dose
  2. Number of Participants With AEs Within 14 Days Post Any DoseTime frame: Up to 14 days post dose
  3. Number of Participants Discontinued From Study Due to AEs Occurring Within 24 Hours Post DoseTime frame: Up to 24 hours post dose
  4. Number of Participants Discontinued From Study Due to AEs Occurring Within 14 Days Post DoseTime frame: Up to 14 days post dose

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.